BioAge Labs, Inc. develops clinical-stage biopharmaceutical candidates for cardiometabolic diseases by targeting the biology of human aging. Its news centers on BGE-102, a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases, including diabetic macular edema.
Recurring updates cover Phase 1 biomarker and tolerability data, indication development for inflammation-driven disease, and research into long-acting injectable and oral small-molecule APJ agonists for obesity. BioAge also reports financial results, public offerings, R&D presentations, and collaborations that use its human longevity data platform to identify metabolic-aging pathways.
BioAge Labs (NASDAQ: BIOA) will participate in investor conferences hosted by Stifel, UBS and Jefferies during November 2026.
Chief Strategy Officer BJ Sullivan is scheduled for fireside chats at Stifel in New York on November 12 and UBS in London on November 16. CEO Kristen Fortney is scheduled for a Jefferies fireside chat in London on November 19. Company representatives will also hold one-on-one meetings.
BioAge Labs (NASDAQ: BIOA) reported a wider third-quarter net loss as it advanced two Phase 2 trials of BGE-102. Net loss was $33.504 million, or $0.73 per share, versus $20.171 million, or $0.56 per share, a year earlier. Collaboration revenue fell to $298,000 from $2.054 million; research and development expenses rose to $30.233 million from $18.513 million.
The first QUELL-DME participant was dosed in September 2026, with topline results anticipated in the second half of 2027. QUELL-CV completed enrollment of approximately 160 participants, with topline data anticipated in the fourth quarter of 2026. BioAge intends to submit its first APJ program investigational new drug application by year-end 2026. Cash, cash equivalents and marketable securities totaled approximately $352.3 million at September 30, 2026; BioAge estimates funding will cover operations and capital expenses through 2029.
BioArctic (BIOA B) received notice that Novartis Pharma has decided to terminate their agreement exploring a potential combination treatment. The Option, Collaboration and License Agreement, entered into in August 2025, paired BioArctic's BrainTransporter technology with an undisclosed Novartis antibody. BioArctic said the termination follows Novartis's decision to discontinue the program and is unrelated to BrainTransporter.
BioArctic will retain the full USD 30 million upfront payment and recognize its remaining unrecognized portion as revenue in 2026. The company has entered into five collaboration agreements using BrainTransporter to date.
BioArctic (BIOA B) has appointed its Nomination Committee to prepare proposals for the company's 2027 Annual General Meeting.
The committee comprises Margareta Öhrvall, appointed by Demban; Pär Gellerfors, appointed by Ackelsta; and chair Thomas Ehlin, representing Fjärde AP-fonden. The Board Chair serves as convener. The represented shareholders held approximately 57 percent of shares and 82 percent of votes as of September 30, 2026. The annual meeting will take place in Stockholm on May 27, 2027, at 4.30 pm CEST. Committee proposals will appear in the meeting notice and on the company's website.
BioAge Labs (BIOA) will participate in two investor conferences on September 29 and 30, 2026.
Company representatives will hold one-on-one meetings at the ROTH Healthcare Opportunities Conference in New York on September 29 and the Stifel Virtual Cardiometabolic Forum on September 30. Chief Strategy Officer BJ Sullivan is scheduled for a Stifel fireside chat at 1 PM EDT.
BioAge Labs (BIOA) has dosed the first participant in QUELL-DME, a randomized, controlled Phase 2 trial of once-daily oral NLRP3 inhibitor BGE-102 in adults with diabetic macular edema (DME).
The approximately 180-participant study will test BGE-102 both as monotherapy and in combination with standard-of-care intravitreal anti-VEGF therapy. Participants are randomized 1:1:1 to three arms: anti-VEGF plus oral placebo, anti-VEGF plus BGE-102 90 mg once daily, or sham intravitreal injection plus BGE-102 90 mg once daily. Treatment lasts 12 weeks with a 4‑week follow-up. The primary endpoint is change from baseline in best-corrected visual acuity at week 12, with exploratory endpoints including retinal measures and intraocular and plasma biomarkers. Topline results are anticipated in the second half of 2027.
BioAge Labs (BIOA) will present at three investor conferences in New York in September 2026, featuring fireside chats and one-on-one meetings with senior management.
Events include the Citi Biopharma Back to School Conference (Sept 9–10), Cantor Global Healthcare Conference (Sept 9–11), and Morgan Stanley 24th Annual Global Healthcare Conference (Sept 14–16), with webcast access and 30-day replays available via the company’s investor website.
BioArctic (Nasdaq Stockholm: BIOA B) issued 20,200 new Class B shares in August 2026 following the exercise of 20,200 stock options from the 2019/2028 program approved on May 9, 2019. As of August 31, 2026, BioArctic had a total of 88,744,685 shares outstanding, comprising 74,344,689 listed Class B shares and 14,399,996 unlisted Class A shares. Class A shares carry ten votes per share and Class B shares one vote per share, giving a total of 218,344,649 votes in the company.
BioAge Labs (NASDAQ:BIOA) reported second quarter 2026 collaboration revenue of $2.5 million, roughly flat year over year, and a net loss of $26.1 million (basic and diluted loss per share $0.58) versus a $21.6 million loss a year earlier. Research and development expenses rose to $24.4 million, mainly from higher BGE-102 program costs, while general and administrative expenses were $7.4 million.
As of June 30, 2026, BioAge held $381.3 million in cash, cash equivalents, and marketable securities and estimates funding through 2029. The first participant was dosed in QUELL-CV, a Phase 2 proof-of-concept trial of NLRP3 inhibitor BGE-102 in obesity with inflammation, with topline data expected in 2H 2026. A Phase 1b/2a trial in diabetic macular edema, QUELL-DME, is planned to start mid-2026, with data anticipated mid-2027. BioAge also advanced its APJ agonist programs and continued discovery collaborations with Novartis and Lilly ExploR&D.
BioAge Labs (Nasdaq:BIOA) has dosed the first participant in QUELL-CV, a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept trial of oral NLRP3 inhibitor BGE-102 in adults at elevated cardiovascular risk.
The 12-week trial will enroll ~160 participants across four arms to evaluate three once-daily doses versus placebo, with percent change in high-sensitivity C-reactive protein (hsCRP) as the primary endpoint and topline data expected in the second half of 2026.